Melicoff Ernestina, Spielberg David R, Heinle Jeffrey S, McKenzie E Dean, Hosek Kathleen E, Schrader Anna L, Mallory George B
Department of Pediatrics, Section of Pediatric Pulmonology and.
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas; and.
Ann Am Thorac Soc. 2023 Feb;20(2):254-261. doi: 10.1513/AnnalsATS.202202-093OC.
Since its inception, older children and adolescents have predominated in pediatric lung transplantation. Most pediatric lung transplant programs around the world have transplanted few infants and young children. Early mortality after lung transplantation and inadequate donor organs have been perceived as limitations for success in lung transplantation at this age. Our aim was to describe our experience in a large pediatric lung transplant program with respect to lung transplantation in infants and young children, focusing on diagnosis, waitlist, and mortality. We performed a retrospective review of infants and young children under 3 years of age at the time of transplant in our program from 2002 through 2020. The patient cohort represented a severely morbid recipient group, with the majority hospitalized in the intensive care unit on mechanical ventilation just before transplantation. There was a marked heterogeneity of diagnoses distinct from diagnoses in an older cohort. Waitlist time was shorter than in older age cohorts. There was a decrease in early mortality, lower incidence of allograft rejection, and satisfactory long-term survival in this age group compared with the older cohort and published experience. Severe viral infection was an important cause of early mortality after transplant. Nonetheless, survival is comparable to older patients, with better enduring survival in those who survive the early transplant period in more recent years. Carefully selected infants and young children with end-stage lung and pulmonary vascular disease are appropriate candidates for lung transplantation and are likely underserved by current clinical practice.
自开展以来,大龄儿童和青少年在小儿肺移植中占主导地位。全球大多数小儿肺移植项目很少为婴幼儿进行移植。肺移植后的早期死亡率和供体器官不足被视为该年龄段肺移植成功的限制因素。我们的目的是描述在一个大型小儿肺移植项目中,针对婴幼儿肺移植的经验,重点关注诊断、等待名单和死亡率。我们对2002年至2020年在我们项目中接受移植时年龄在3岁以下的婴幼儿进行了回顾性研究。该患者队列代表了一组病情严重的受者群体,大多数患者在移植前刚刚在重症监护病房接受机械通气治疗。诊断存在明显的异质性,与大龄队列中的诊断不同。等待名单时间比大龄队列短。与大龄队列和已发表的经验相比,该年龄组的早期死亡率有所下降,同种异体移植排斥反应的发生率较低,长期生存率令人满意。严重病毒感染是移植后早期死亡的重要原因。尽管如此,其生存率与大龄患者相当,近年来在早期移植阶段存活下来的患者的持久生存率更高。经过精心挑选的患有终末期肺和肺血管疾病的婴幼儿是肺移植的合适候选者,而目前的临床实践可能未能充分满足他们的需求。